Skip to content

EBITDA margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
27.2%-2.2pp
Amgen logo
AmgenAMGN
41.5%+3.4pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-202.5%-60.0pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-164.8%-51.5pp
Immunome logo
ImmunomeIMNM
-5,886.7%-11,897pp
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-2,749.9%-808pp

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: IDEAYA Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s EBITDA margin?
IDEAYA Biosciences, Inc. (IDYA) reported EBITDA margin of -4,637% in Q4 2024.
How has IDEAYA Biosciences, Inc.'s EBITDA margin changed year-over-year?
IDEAYA Biosciences, Inc.'s EBITDA margin decreased by 721.7% year-over-year, from -564.3% to -4,637%.
What is the long-term trend for IDEAYA Biosciences, Inc.'s EBITDA margin?
Over 3 years (2021 to 2024), IDEAYA Biosciences, Inc.'s EBITDA margin has grown at a 198.8% compound annual growth rate (CAGR), from -173.7% to -4,637%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.